Core Viewpoint - Ensysce Biosciences, Inc. has received a Notice of Allowance from the Brazilian Patent Office for a patent covering additional opioid families, enhancing its intellectual property and expanding global protection for its innovative pain treatment technologies [1] Group 1: Patent and Technology - The newly allowed patent includes both composition of matter and method of use claims, which strengthens the company's intellectual property estate [1] - The patent covers the company's proprietary TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies, aimed at advancing safer pain treatment [1] Group 2: Market Implications - The expansion of patent protection is expected to bolster the company's position in the market for Next Generation analgesics, potentially leading to increased competitiveness and market share [1]

Core Insights - Recent market movements have highlighted significant price changes in several companies, attracting investor attention Company Summaries - **Palisade Bio, Inc. (PALI)**: Experienced an 83.77% price surge to $1.57, supported by a trading volume of 143,677,281. The company raised $120 million through an upsized underwritten public offering, selling 171 million shares at $0.70 each, to advance its novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [1][6] - **Ouster, Inc. (OUSTZ)**: Saw a 76.55% price increase to $0.09, with a volume of 150,580. This reflects growing confidence in Ouster's high-resolution lidar technology, which serves various industries including automotive and robotics [2][6] - **Ryvyl Inc. (RVYL)**: Formerly known as GreenBox POS, experienced a 72.64% price jump to $0.511, supported by a substantial volume of 231,813,941. The company focuses on blockchain-based payment solutions, showcasing resilience and innovation in the technology sector [3] - **Klotho Neurosciences, Inc. (KLTOW)**: Saw a 50.11% price increase to $0.14, with a volume of 134,508. The company is advancing gene therapy product candidates, and its ALS therapy received Orphan Drug Designation from the U.S. FDA, contributing to a rise in shares [4] Industry Overview - The top gainers reflect diverse industries, including biotechnology, healthcare, technology, and financial services, underscoring the dynamic nature of the market and varied investment opportunities [5]